2018 CDCN Highlights!

2018 has been an amazing year for the CDCN! In honor of all the progress that we have recently made thanks to support of hundreds of patients, loved ones, and community members from around the world, we wanted to high… READ MORE

Fourth Annual Quest for a Cure!

The Fourth Annual Quest for a Cure Gala was an incredible success! Quest for a Cure was held on November 16, 2018 at the beautiful Arts Ballroom in Philadelphia, PA. Our CDCN community of patients, loved ones, an… READ MORE

CDCN Research Identifies Lab Tests Predictive of Siltuximab Response in iMCD

The Castleman Disease Collaborative Network (CDCN) is excited to announce the recent publication of a study that identified key laboratory markers that help to predict whether patients with idiopathic multicentric Cas… READ MORE

CDCN at the 2018 ASH Conference!

The Castleman Disease Collaborative Network had its best showing yet at the American Society of Hematology’s Annual Meeting and Exposition, the premier event of the global hematology community! This year, A… READ MORE

Fifth Annual Patient & Loved One Summit

The 2018 Patient and Loved One Summit was a hit! The fifth annual summit took place on September 21-22, 2018 at the University of Pennsylvania and brought together over 90 patients, loved ones, and CDCN volunte… READ MORE

First-Ever Treatment Guidelines for Idiopathic Multicentric Castleman Disease!

With the CDCN's leadership, another major milestone has been achieved in the fight against Castleman Disease! The CDCN convened 42 experts from 10 different countries to establish the first-ever tr… READ MORE

New French reference center for Castleman disease holds launch meeting: Dr. Eric Oksenhendler, CDCN Vice Chair of Treatment Guidelines/Patient Care, at the helm

In early June 2018, a new French reference center for Castleman disease held a launch meeting in Paris,“Premiere Journee du Centre de Référence ‘Maladie de Castleman’.”  The … READ MORE

Patient Funded Research Study Reveals Critical New Information About CD

      The Castleman Disease Collaborative Network (CDCN) is proud to announce the publication of our SPEED I (Serum Proteomics Evaluation for Etiology and Pathogenesis Data I) research study in t… READ MORE

Partnership Spotlight: Janssen Research and Development, LLC.

After another great year for the CDCN in 2017, we'd like to recognize a crucial partner in the fight against Castleman disease: Janssen Research and Development, LLC. Check out members the Janssen team&nbs… READ MORE

Castleman Disease Collaborative Network Funds Four High Impact Grants!

The Castleman Disease Collaborative Network (CDCN) is excited to announce funding for four high impact research proposals! All four research projects were awarded individual grants of $42,000. Dr. David Fajgenbaum,… READ MORE